HARMONIZE
2014
Sodium Zirconium Cyclosilicate in Hyperkalaemia
In 258 patients with hyperkalaemia, sodium zirconium cyclosilicate maintained normokalaemia compared with placebo.
Result
Primary endpoint: Mean serum potassium during days 8–29
Mean serum potassium days 8–29: 4.8/4.5/4.4 mEq/L (5/10/15 g) vs 5.1 with placebo (all p<0.001).
- Subtopic
- Hyperkalaemia
- Design
- Phase 3 RCT with an open-label run-in
- Relevance
- Supporting: context rather than must-know.
- Source
- Kosiborod M, et al. JAMA. 2014;312(21):2223-2233.doi 10.1001/jama.2014.15688
Discussion & critique
Led to approval of sodium zirconium cyclosilicate (Lokelma) for hyperkalaemia.